Jump to content

Talk:Glembatumumab vedotin

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Dec 2012 poster of EMERGE final results

[edit]

The EMERGE study shows the results presented in Dec 2012. Its conclusions are :

"EMERGE results consistent with previous study in similar population
* CDX-011 well-tolerated
 ‒ Less hematologic toxicity but more rash and neuropathy than Investigator’s Choice (IC)
* Promising activity in triple-negative breast cancer (TNBC), where treatment options are limited
 ‒ CDX-011 response rate of 19% in TNBC compared to 0% for IC
* Significant tumor expression of GPNMB associated with greater activity
 ‒ CDX-011 response rate of 32% compared to 13% for IC
 ‒ Stromal expression of GPNMB did not appear to correlate with outcome.
 ‒ High GPNMB expression in 41% of patients with TNBC
 ‒ CDX-011 response rate of 33% and doubling of PFS (p=0.008) and OS (p=0.003)
* A registrational study is being planned."

Could mention PFS etc in main article. - Rod57 (talk) 00:46, 4 February 2013 (UTC)[reply]